Curcuma longa L. Prevents Hepatotoxicity Induced Isoniazid and Rifampicin: An Experiment in Wistar Rats Model
DOI:
https://doi.org/10.15850/amj.v11n2.3161Keywords:
Curcuma longa L., hepatotoxicity, isoniazid, oxidative stress, rifampicinAbstract
Background: Hepatotoxicity induced by the combination of isoniazid (INH) and rifampicin (RIF) in the treatment of tuberculosis (TB) remains a major concern. Oxidative stress has a role in mechanism of hepatotoxicity. Curcuma longa L. has been widely used as a traditional medicine and has shown antioxidant activity. This study aimed to provide evidence of Curcuma longa L as protection against oxidative stress induced by isoniazid and rifampicin therapy.
Methods: This was an experimental study on male Wistar rats weighing 150-200 grams, aged 8-10 weeks which were divided into a negative control group (K0), a positive control group with INH + RIF (K1), a treatment group with a dose of 2.2 gr/kg/day Curcuma longa L powder (K2), and treatment group with INH+RIF and additional 2.2 gr/kg/day turmeric rhizome powder (K2+). SGOT and SGPT were measured from blood plasma on the 28th day; then hepatic tissue was obtained to measure MDA levels and observed histologically. Statistical analysis was done using ANOVA and continued with Duncan procedure using SPSS ver. 27.
Results: SGOT, SGPT, the highest average MDA level in the liver, and the highest mean necrotic cell count in the positive control group showed a significant difference (p<0.05). The treatment group had a smaller average number of necrotic cells than the positive control group with a significant difference (p <0.05).
Conclusion: Curcuma longa L powder has been shown to prevent elevation in SGOT, SGPT, MDA of liver tissue and hepatocyte necrosis, indicating its potential in protecting the liver from oxidative stress.
Downloads
Published
Issue
Section
License
- Authors retain copyright and grant Althea Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in Althea Medical Journal. Althea Medical Journal is licensed under CC BY-NC 4.0
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Althea Medical Journal.